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By using whole-exome sequencing, we identified a homozygous guanine-to-adenine transition at the invariant 1 position of the
acceptor site of intron 1 (c.971G>A) in solute carrier organic anion transporter family member 2A1 (SLCO2A1), which encodes a pros-
taglandin transporter protein, as the causative mutation in a single individual with primary hypertrophic osteoarthropathy (PHO) from
a consanguineous family. In two other affected individuals with PHO from two unrelated nonconsanguineous families, we identified
two different compound heterozygous mutations by using Sanger sequencing. These findings confirm that SLCO2A1mutations inacti-
vate prostaglandin E2 (PGE2) transport, and they indicate that mutations in SLCO2A1 are the pathogenic cause of PHO. Moreover, this
study might also help to explain the cause of secondary hypertrophic osteoarthropathy.Primary hypertrophic osteoarthropathy (PHO [MIM
167100]), also named pachydermoperiostosis, is a rare
genetic disease that affects both skin and bones. PHO is
characterized by clubbed nails, periostosis, acroosteolysis,
painful joint enlargement, and skin manifestations that
include thickened facial skin, a thickened scalp, and coarse
facial features.1 Uppal et al.2 revealed that homozygous
mutations in HPGD (MIM 601688), which encodes
15-hydroxyprostaglandin dehydrogenase (15-PGDH), cause
PHO and that increased levels of prostaglandin E2 (PGE2)
are involved in the pathogenesis of PHO. Subsequently,
a number of cases of PHO and isolated, congenital clubbed
nails were found to display mutations in HPGD.3–8
However, no HPGD mutation was detected in either the
proband (14-year-old boy) or the 19-year-old brother of
the proband from a consanguineous Moroccan family
affected by PHO.9 We also failed to identify an HPGD
mutation in the proband from a consanguineous Chinese
family affected by PHO. These findings support genetic
heterogeneity of PHO and suggest that a potential causa-
tive genetic mutation is located in these affected individ-
uals. Researchers have recently applied exome sequencing
to rare heritable diseases in order to successfully identify
causative genetic mutations.10–14 Here, we report on a
homozygous guanine-to-adenine transition at the in-
variant 1 position of the acceptor site of intron 1
(c.971G>A) in solute carrier organic anion trans-
porter family member 2A1 (SLCO2A1) (MIM 601460,
NM_005630.2), which encodes a prostaglandin trans-
porter protein, as the causative mutation in a single
PHO-affected individual from a consanguineous family.
In two other PHO-affected individuals from two unrelated
nonconsanguineous families, we identify two different
compound heterozygous mutations. These findings con-
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The pedigrees of the three Han Chinese families with
PHO are shown in Figure 1. In family 1, a 24-year-old
man (proband, family1-P1, IV.4 in family 1 in Figure 1)
is the only son of consanguineous parents who are first
cousins. In families 2 and 3, the probands, a 27-year-old
man (family2-P2; III.5 in family 2 in Figure 1) and a
21-year-old man (family3-P3; III.1 in family 3 in Figure 1),
respectively, are the only sons of nonconsanguineous
parents. The disease was diagnosed in the affected persons
with the use of clinical and radiological criteria. Disease
onset in the three individuals occurred at 12–15 years of
age and manifested as digital clubbing, swelling of the
knees, periostosis, and a progressive thickening and fur-
rowing of facial skin (Figure 2 and Figure S1, available
online). The individual from family 2 had a stomach
hemorrhage due to a gastric ulcer at 21 years of age. Phys-
ical examination revealed that the individuals had no
other secondary hypertrophic osteoarthropathy, such as
heart or lung abnormities, Graves disease, or inflammatory
bowel disease. No other affected individuals were found in
the three families. This study was approved by the ethics
committee of the Shanghai Sixth People’s Hospital, (affili-
ated with Shanghai Jiao Tong University). Written in-
formed consent was obtained from all of the subjects
who contributed DNA and clinical information to the
study. Families 1, 2, and 3 were from Jiangsu, Anhui, and
Shandong, respectively. The numbers of participating indi-
viduals from families 1, 2, and 3 were 16, 20, and 3, respec-
tively (Figure 1). Venous blood samples were obtained
from 39 individuals (three affected and 36 unaffected)
from three unrelated PHO families. We extracted genomic
DNA from whole blood by using standard methods. All
subjects are of Chinese Han ethnicity.rosis and Bone Diseases, Shanghai Jiao Tong University and Shanghai Sixth
, Department of Endocrinology, Ministry of Health, Peking Union Medical
a
Genetics. All rights reserved.
an Journal of Human Genetics 90, 125–132, January 13, 2012 125
Figure 1. The Pedigrees of the Chinese Families
Affected by PHO
Black symbols represent the affected individuals,
open symbols represent the unaffected individ-
uals, and the half-blackened symbols represent
asymptomatic mutation carriers. Circles and
squares indicate females and males, respectively.
The arrows identify the probands in the families.
Double lines indicate consanguineous marriages.
All living individuals were the individuals avail-
able for genotyping in families 1, 2, and 3.We first sequenced the exome of a single PHO-affected
individual (family1-P1) from a consanguineous family.
Exon-enriched DNA from the proband of family 1 was
sequenced with the Illumina Genome Analyzer II platform
according to the manufacturer’s (Illumina’s) instructions.126 The American Journal of Human Genetics 90, 125–132, January 13, 2012The raw image files were processed with
Illumina Base Calling Software 1.7 with
default parameters, and the sequences of
each individual were reported as 90 bp
paired-end reads. Sequence reads were map-
ped to a reference genome (UCSC Genome
Browser hg18 assembly) with SOAP2 (BGI-
Shenzhen).15–17 The SOAPsnp results were
filtered as follows: The base quality was
equal to or more than 20, and the se-
quencing depth was between 4 and 200,
whereas the estimated copy number was
less than two, and the distance between
two SNPs was more than 5 bp.12,18 Approx-
imately 1.26 gigabases (Gb) of high-quality
data were aligned to the targeted regions
for family1-P1 with a per-base mismatch
rate of 0.37%, resulting in an average read
depth of 33.53 for the individual exome
(Table S1). We identified 31,738 SNPs, of
which 7,038were splice-site and nonsynon-
ymous variants (SS-NSVs) in the target
region (Table S2). By filtering the data with
public SNP databases, including dbSNP129,
the UCSC Genome Browser hg18 assembly,the 1000 Genomes Browser, and the YanHuang Genome
Database (provided by the Beijing Genomics Institute),
we identified 472 nonsynonymous (NS) and splice-site
(SS) substitutions as candidate SNPs (Table S3). Because of
the recessive nature of this consanguineous family affectedFigure 2. Clinical Images of the Affected
Individual, Family1-P1
The images show the thickening and fur-
rowing of facial skin (A) and the clubbing
of fingernails and toenails (B and C).
Hand radiographs show a loss of the nor-
mal tabulation of metacarpals and pha-
langes and cortical thickening of the meta-
carpals and the proximal and middle
phalanges (D and E). A radiograph of the
feet shows cortical thickening and acroos-
teolysis (F). A radiograph of a knee shows
periosteal hyperostosis of the knee region
and shows patellae sclerosis and sclerosis
of both the distal femur and tibiofibula
(G). All images are published with permis-
sion from the affected individual.
Figure 3. Locating and Sequencing the SLCO2A1 Mutations
(A) The location of the mutations identified in the SLCO2A1 gene. Family1-P1 (P1) had a homozygous mutation, and the father (F) and
mother (M) were both heterozygous carriers. Family2-P2 (P2) and family3-P3 (P3) had compound heterozygous mutations, and their
fathers and mothers were heterozygous carriers.
(B) Both the p.Gly222Arg and p.Gly255Glu heterozygous missense mutations occur at a highly conserved position in SLCO2A1, as
shown by a comparison of the corresponding sequences of ten vertebrates. The bases that are identical to those in Homo sapiens are
highlighted in blue. Abbreviations are as follows: Homo, Homo sapiens; Xenopus, Xenopus laevis; Macaca, Macaca mulatta; Canis, Canis
lupus familiaris; Sus, Sus scrofa; Bos, Bos taurus; Rattus, Rattus norvegicus; Mus,Mus musculus; Gallus, Gallus gallus; and Danio,Danio rerio.
(C) Twomissensemutations (p.Gly222Arg and p.Gly255Glu) in the transmembranemodel of SLCO2A1. Themutations are indicated by
arrows.by PHO, our subsequent validation analyses focused
on homozygous nonsynonymous variants in coding
sequences. In family1-P1, we identified 28 genes that con-
tained homozygous missense, nonsense, or splicing muta-
tions (Table S4). However, a thorough literature review sug-
gested that among these genes, only SLCO2A1 appears to
be a functional candidate. A previous study clearly demon-
strated that SLCO2A1 is associated with the transport,The Americclearance, and degradation of PGE2.
19 Sanger sequencing
confirmed a homozygous guanine-to-adenine transition
at the invariant 1 position of the acceptor site of intron 1
(c.971G>A) in SLCO2A1 (Figure 3A) of the proband, and
each of his healthy parents was found to have a heterozy-
gous mutation at this site. We also confirmed by using
Sanger sequencing that some relatives of the proband,
including II-2, II-6, III-5, III-7, III-8, and III-9 in family 1,an Journal of Human Genetics 90, 125–132, January 13, 2012 127
were heterozygous carriers (Figure 1). The identified muta-
tion was not detected in chromosomes from 250 ethnically
matched control individuals.
By using direct Sanger sequencing, we identified two
unrelated PHO-affected individuals (family2-P2 and
family3-P3) from two nonconsanguineous families as
having compound heterozygous mutations in SLCO2A1:
Family2-P2 had a missense mutation (c.764G>A
[p.Gly255Glu]) in exon 6 combined with a frameshift
mutation (c.1634delA) in exon 12, and family3-P3 had
a missense mutation (c.664G>A [p.Gly222Arg]) in exon 5
combined with a guanine-to-adenine transition at the
invariant þ1 position of the acceptor site of intron 7
(c.940þ1G>A) (Figure 3A). The single-base deletion in
SLCO2A1 results in a frameshift and a premature termina-
tion codon (p.Asn545Thrfs*15), and the c.940þ1G>Amu-
tation is predicted to cause an abnormal splicing event.
The healthy parents of family2-P2 each carried either
c.764G>A or c.1634delA as a heterozygous mutation, and
we also confirmed that some relatives of family2-P2,
including I-3, II-2, II-5, II-7, II-8, and IV-2, were heterozy-
gous carriers (Figure 1). In addition, the healthy parents of
family3-P3 were found to carry heterozygous mutations
(c.664G>A or c.940þ1G>A). Accordingly, all three genetic
variants identified in the three PHO-affected individuals
from three independent families were not spontaneous
mutations, but rather were inherited. We detected none of
the observed mutations in 250 unrelated, ethnically
matched control individuals. These results indicate that in
addition to HPGD mutations, the identified mutations in
SLCO2A1 are the cause of PHO.
SLCO2A1 encodes an organic anion-transporting poly-
peptide (OATP2A1) (NP_005621.2) (named prostaglandin
transporter [PGT]) that is located on chromosome 3q21.
SLCO2A1 is organized into 14 exons that encode a 643
amino acid, 12-transmembrane-domain organic anion
cell-surface transporter.19–21 SLCO2A1 is widely expressed
in various peripheral tissues and in the brain of several
mammalian species, including humans.19–21 To date, an
exact understanding of the role of OATP2A1 in pro-
staglandin (PG) metabolism remains unclear. Many
researchers have postulated three possible roles for
OATP2A1.19–22 First, OATP2A1 might mediate the efflux
of newly synthesized PGs from cells. Second, OATP2A1
might mediate epithelial PG transport. Third, OATP2A1
could mediate PG clearance and degradation. Indeed,
many studies have determined that the magnitude of
the effects of PGs depends not only on their production
but also on their metabolism. Kanai et al.20 identified
OATP2A1 and found that OATP2A1 removes PGs from
the extracellular compartment. PGT delivers PGs to cyto-
plasmic HPGD, resulting in their oxidation and inactiva-
tion.20,23,24 However, until now, no disease has been
reported as being associated with a SLCO2A1 muta-
tion. In this study, among the three individuals with
PHO, we detected a homozygous splice-site mutation
(c.971G>A), a compound heterozygous missense128 The American Journal of Human Genetics 90, 125–132, January 1(c.664G>A [p.Gly222Arg]) plus splice-site (c.940þ1G>A)
mutation, and a compound heterozygous missense
(c.764G>A [p.Gly255Glu]) plus frameshift (c.1634delA)
mutation in SLCO2A1. Both the p.Gly222Arg and
p.Gly255Glu heterozygous missense mutations are at
highly conserved positions (Figure 3B) and are likely to
be functionally damaging (Figure 3C). To illustrate the
effects of the two missense mutations in exons, we
modeled the structure of SLCO2A1 on the crystal structure
of a glycerol-3-phosphate transporter (GlpT, PDB ID
1pw4). A molecular model of SLCO2A1 was constructed
with the SWISS-MODEL server and Swiss-PdbViewer,25,26
which retrieved the template structure, 1pw4, from
PDB.27 The resulting models were evaluated on the basis
of the energy values that were calculated with the
MODELER28 and SWISS model-structure assessment
tools. The mutant structure was also built with Swiss-
PdbViewer.25,26 PGE2 was docked in the SWISS dock server,
which is based on the EADock DSS pipeline.29 Structural
graphics and visualization were both based on PyMol
and Swiss-PdbViewer. Although the identity was only
16%, all of the 12 helix regions were covered. According
to the predicted structure, the mutant Gly222Arg is local-
ized at helix 5 (H5). The p.Gly255Glu mutation is located
in the connecting loop of H5 and the periplasmic end of
helix 6 (H6). PGE2 docks to the modeled structure and
appears to occupy a pocket similar to that of GlpT (Fig-
ure 4A). Two significant features of the p.Gly222Arg muta-
tion could make the membrane transporter dysfunctional.
First, the p.Gly222Arg mutation could disturb the positive
electrostatic potential of the substrate-binding surface by
adding an additional positively charged residue.27,30
Second, the larger side chain could break the rocker switch
of H127 by terminating the helical structure of H1 and
changing the N-Ca dihedral angles (4) of Tyr48 from
68.8 to 92.8 and the Ca-C angles (c) from 24.6 to
84.0 (Figures 4B and 4C). Although the p.Gly255Glu
mutation is not predicted to affect the function of
SLCO2A1, the mutation might alter the structure of the
sixth transmembrane domain as a result of the substitu-
tion of a macromolecular hydrophilic amino acid (Glu)
for a micromolecular hydrophobic amino acid (Gly).
Furthermore, in the protein with the latter mutation,
we found another heterozygous single-base-deletion
(c.1634delA), which would result in a frameshift and a
premature termination codon (p.Asn545Thrfs*15). There-
fore, we predicted that this single-base-deletion would
lead to a loss of the eleventh and twelfth transmembrane
domains. Similarly, although family3-P3 carried a predicted
functional heterozygous p.G222R mutation, the mutation
occurred in combination with a c.940þ1G>A splice-site
mutation. The latter mutation would result in the skipping
of exon 7, leading to a frameshift and a premature termina-
tion codon (p.Arg288Glyfs*6). To assess the effect of the
c.971G>A mutation in SLCO2A1 on splicing, we ampli-
fied the cDNA fragments between exons 1 and 3 with
RT-PCR of family1-P1 and the control individual. Total3, 2012
Figure 4. Protein Modeling of the
SLCO2A1 p.Gly222Arg Mutation
(A) The wild-type structure of SLCO2A1.
H1, H5, and H6 represent three of the
twelve helices in the protein structure.
Two amino acids of interest, Gly222 and
Gly255, are labeled and shown in the
Corey, Pauling, Koltun (CPK) model. The
mesh grid surface and the CPK molecule
represent docked PGE2 in the middle of
the structure.
(B and C) The effect of the p.Gly222Arg
mutant on the interaction between H1
andH5. Gly222 of H5 and the neighboring
portion of H1 are shown in green and
blue, respectively. The shortest distances
between these two parts of H1 and H5 are
1.74 A˚ and 2.82 A˚ at the labeled positions
in the p.Gly222Arg mutant and wild-type
proteins, respectively. The symbols F and
c represent the dihedral angles of Tyr48
in H1.RNA was extracted from the conchal cartilage of family1-
P1 and from the articular cartilage of the control individ-
ual’s knee, respectively. The expected 340 bp fragment
was only seen in the control individual, whereas an extra
short 202 bp fragment was found in the affected indi-
vidual. Furthermore, we confirmed that exon 2 was skip-
ped, which lead to the loss of 46 acid residues in SLCO2A1
(p.Val33_Glu78del) (Figure S2). All the assay results were
consistent with the conclusion that autosomal-recessive
PHO can be caused by the loss of SLCO2A1 function as
a result of either a homozygous mutation or compound
heterozygous mutations.
Uppal et al.2 revealed that PHO pathogenesis occurs
through increased levels of PGE2. In this study, plasma
and urine samples were collected from three affected indi-
viduals and 36 unaffected individuals from three unrelated
families. Early-morning plasma and urine samples were
collected after the individuals had fasted, and the samples
were immediately frozen. The concentrations of PGE2 and
13,14 dihydro,15 ketometabolites (PGE-M) were measured
in three assays at different sample dilutions with com-
petitive enzyme-linked immunosorbent assays (Cayman
Chemical), and data were analyzed with the manufac-
turer’s analysis tools. We observed that urinary PGE2 levels
were significantly elevated in the three affected individ-
uals, who were found to have PGE2 levels that were sixteen
times higher than those of the unaffected controls. How-
ever, no significant difference in urinary PGE2 levels was
found between the heterozygous individuals from familiesThe American Journal of Human Ge1 and 2 and the unaffected controls
(Table 1). Unexpectedly, we found
that the concentration of urinary
PGE-M was significantly higher in
the three affected individuals than
in the heterozygous carriers and unaf-
fected controls. However, compared
with the levels in the unaffectedcontrol individuals, the urinary PGE-M concentrations in
the three affected individuals were only six times higher.
We also found that plasma PGE-M levels were higher in
the affected individuals than in the heterozygous carriers
and unaffected controls. Our results differ from those asso-
ciated with homozygous HPGD mutations, which cause
a significant increase in urinary PGE2 levels and a decrease
in urinary PGE-M levels in affected individuals.2 The differ-
encemight be attributable to the fact that the affected indi-
viduals with SLCO2A1 mutations had normal 15-PGDH
function, but this speculation will require further investi-
gation. Our findings demonstrate that in affected individ-
uals with SLCO2A1mutations, a portion of PGE2 is cleared
and degraded, which indicates the inactivation of PGE2
transport by SLCO2A1. To determine the role of PGT in
ductus arteriosus closure, Chang et al.31 used global PGT-
knockout mice (PGT/). They observed that urinary
PGE2 levels were significantly higher in PGT
/ mice than
in PGTþ/þ mice and that plasma PGE2 metabolite concen-
trations decreased significantly in PGT/ mice. These
results are consistent with the fact that PGT-null mice fail
to metabolize PGE2. However, they did not describe the
pathogenesis of PHO in PGT/ mice. Clarifying whether
the PHO phenotype is indeed restricted to humans with
a loss of SLCO2A1 will require detailed bone analyses in
PGT/ mice. Our findings are partially consistent with
the above results, and the affected individuals with muta-
tions showed significantly higher urinary PGE2 concentra-
tions and relatively low plasma PGE-M levels. In fact,netics 90, 125–132, January 13, 2012 129
Table 1. Measurement of the Concentration of Urinary PGE2, Urinary PGE-M, and Plasma PGE-M in the Affected Individuals, the
Heterozygous Carriers, and the Unaffected Controls
Urinary PGE2 (ng/mmol creatinine) Urinary PGE-M (ng/mmol creatinine) Plasma PGE-M (pg/ml)
Affected individuals (n ¼ 3) 439.3 5 234.9 200.0 5 123.1 46.9 5 14.4
Heterozygous carriers (n ¼ 10) 30.0 520.1 18.9 5 6.5 18.2 5 10.5
Unaffected controls (n ¼ 5) 26.8 5 7.5 30.9 5 16.9 20.2 5 7.7
p value 0.003 0.000 0.044
Three separate early-morning urine samples were measured in the individuals with homozygous or compound heterozygous SLCO2A1 mutations and the
unaffected controls. The standard deviations represent the intra-assay variation of the three assays with different sample dilutions.patent ductus arteriosus (PDA), as well as other congenital
heart defects, is common in affected individuals with
HPGD mutations. However, by using echocardiography,
we found neither PDA nor other heart defects in the three
affected individuals with SLCO2A1 mutations. We found
that the three affected individuals with SLCO2A1 muta-
tions seemed to be the most severely affected in the skin,
bones, and knees; however, HPGD mutations were associ-
ated with mild PHO, characterized by either the absence
of pachydermia or the presence of mild periostosis.3,7,9
Of course, to assess phenotypic differences between
affected individuals with HPGD mutations and those with
SLCO2A1 mutations, we need more cases with SLCO2A1
mutations.
Although Uppal et al. found the pathogenic mechanism
of PHO to be associated with increased concentrations of
plasma PGE2,
2 the cause of secondary hypertrophic osteo-
arthropathy (SHO) has not been completely elucidated.
Coggins et al.32 said that explaining the pathogenesis of
SHO without a primary insult to the lungs or pulmonary
blood flow, as is found in Graves disease and inflammatory
bowel disease, is very difficult to do on the basis of the
HPGD mutation in PHO. Our findings suggest that the
dysregulated levels of PGE2 in Graves disease and inflam-
matory bowel disease might be due to the inactivation of
SLCO2A1 rather than to the loss of 15-PGDH function.
Graves disease and inflammatory bowel disease are auto-
immune disorders, andmany previous studies have shown
the dysregulation of PGE2 in these diseases by using
in vitro and in vivo techniques.33,34 In fact, this PGE2
transport is the rate-limiting step of PGE2 inactivation, at
least in the lungs.35 We speculate that the production of
cytokines in inflammatory cells in Graves disease and in-
flammatory bowel disease might influence the SLCO2A1-
associated transmembrane transport of PGE2. Therefore,
determining whether SHO associated with Graves disease
or inflammatory bowel disease is caused by inactivated
SLCO2A1 resulting from either mutations in SLCO2A1 or
other causes will require further study.
In summary, our findings confirm that SLCO2A1 muta-
tions inactivate PGE2 transport, and they indicate that
mutations in SLCO2A1 are the pathogenic cause of PHO.
Moreover, these results might also help to explain the
cause of SHO. This study shows the advantage of using
exome sequencing to identify genetic mutations associ-130 The American Journal of Human Genetics 90, 125–132, January 1ated with inherited disorders, especially in cases of small
families and sporadic occurrence.Supplemental Data
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be found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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